Subsequently, we determined that comprehensive patterns of changes, such as EGFR amplification, a combination of whole chromosome 7 gain and whole chromosome 10 loss (7 + /10−), or TERT promoter (pTERT) mutations, lead pathologically diagnosed low-grade gliomas to exhibit adverse outcomes similar to those of GBM [9]. This evidence concerns the gene EGFR and glioblastoma.